Carlo Traverso, PhD
Gastroenterology · Boston, MANPI 1407976392
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $395,299 of the $447,481 with a category attached, or 88.3%. Novo Nordisk AS accounts for 87.1% of it on its own, with 5 other manufacturers making up the rest. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $6215.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$390K
- Novo Nordisk$54K
- Pfizer$2K
- Vertex$1K
- Eagle Pharmaceuticals, Inc.$750
- Novo Nordisk US Research & Development, Inc.$33
Across 2 payments — averaging $269,630 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$539K
What the payments were for
- Consulting fees$395,29988%
- Speaking & faculty fees$3,1901%
- Travel & lodging$33,9328%
- Food & beverage$15,0603%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 50 | $389,569 |
| Novo Nordisk | 17 | $53,938 |
| Pfizer | 1 | $2,000 |
| Vertex | 1 | $1,190 |
| Eagle Pharmaceuticals, Inc. | 1 | $750 |
| Novo Nordisk US Research & Development, Inc. | 2 | $33 |
How this compares
$447,481 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
- Scott SnapperBoston$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.